2023 World Conference on Lung Cancer (Posters)-P2.09. Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression

Pdf Summary

A study presented at the WCLC 2023 conference explored the efficacy of increased doses of aumolertinib in patients with metastatic non-small cell lung cancer (NSCLC) who experienced gradual progression after treatment with aumolertinib. With the widespread use of third-generation EGFR-TKIs in NSCLC, acquired resistance has become a clinical problem. The study aimed to investigate whether a higher dose of aumolertinib would benefit patients who experienced gradual progression after initial treatment.<br /><br />The study included patients with histologically confirmed unresectable, locally advanced, or metastatic NSCLC. Patients were divided into two cohorts, with cohort 1 receiving aumolertinib as first-line treatment and cohort 2 as second-line treatment. When patients experienced gradual progression, a high dose of aumolertinib (165mg qd/220mg qd) was administered.<br /><br />In the cohort 1 group, the median progression-free survival (PFS1) for standard-dose aumolertinib was 16 months. Aumolertinib dosage was increased to 165mg in 5 cases and 220mg in 15 cases, depending on the presence of brain metastasis. The median PFS2 (time from gradual progression to disease progression) has not been reached yet, with PFS2 rates at 6 and 12 months being 95% and 80%, respectively. The objective response rate (ORR) was 75%, and the disease control rate (DCR) was 100% in the PFS2 period.<br /><br />In cohort 2, the dosage of aumolertinib was increased for ten patients, with an ORR of 10% and a DCR of 90% at the gradual progression stage. No new safety signals were identified, and common drug-related toxicities were mild rash and diarrhea.<br /><br />The study concluded that an increased dose of aumolertinib demonstrated extended effectiveness in the treatment of EGFR-mutated NSCLC with gradual progression, even in the presence of brain metastases. The higher doses of aumolertinib were well-tolerated with no significant increase in adverse events. The study suggests that increasing the dose of aumolertinib may be a viable approach for these patients, but further research and observation are needed.

Asset Subtitle

Jun Li

Meta Tag

Speaker Jun Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023

efficacy

increased doses

aumolertinib

metastatic non-small cell lung cancer

NSCLC

gradual progression

third-generation EGFR-TKIs

acquired resistance

clinical problem